Evonik Evonik

X

Find Rucaparib Camsylate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

0

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Rucaparib Camsylate
Also known as: 1859053-21-6, Rucaparib (camsylate), Rucaparib (monocamsylate), Pf-1367338-bw, C0-338, [(1s,4r)-7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]methanesulfonic acid;6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one
Molecular Formula
C29H34FN3O5S
Molecular Weight
555.7  g/mol
InChI Key
INBJJAFXHQQSRW-STOWLHSFSA-N
FDA UNII
41AX9SJ8KO

Rucaparib Camsylate is the camsylate salt form of rucaparib, an orally bioavailable tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) 1 (PARP1), 2 (PARP2) and 3 (PARP3), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, rucaparib selectively binds to PARP1, 2 and 3 and inhibits PARP-mediated DNA repair. This enhances the accumulation of DNA strand breaks, promotes genomic instability and induces cell cycle arrest and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARPs are enzymes activated by single-strand DNA breaks that catalyze the post-translational ADP-ribosylation of nuclear proteins, which induces signaling and the recruitment of other proteins to repair damaged DNA. The PARP-mediated repair pathway plays a key role in DNA repair and is dysregulated in a variety of cancer cell types.
1 2D Structure

Rucaparib Camsylate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[(1S,4R)-7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]methanesulfonic acid;6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one
2.1.2 InChI
InChI=1S/C19H18FN3O.C10H16O4S/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15;1-9(2)7-3-4-10(9,8(11)5-7)6-15(12,13)14/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24);7H,3-6H2,1-2H3,(H,12,13,14)/t;7-,10-/m.1/s1
2.1.3 InChI Key
INBJJAFXHQQSRW-STOWLHSFSA-N
2.1.4 Canonical SMILES
CC1(C2CCC1(C(=O)C2)CS(=O)(=O)O)C.CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2
2.1.5 Isomeric SMILES
CC1([C@@H]2CC[C@]1(C(=O)C2)CS(=O)(=O)O)C.CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2
2.2 Other Identifiers
2.2.1 UNII
41AX9SJ8KO
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 1859053-21-6

2. Rucaparib (camsylate)

3. Rucaparib (monocamsylate)

4. Pf-1367338-bw

5. C0-338

6. [(1s,4r)-7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]methanesulfonic Acid;6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one

7. Co-338

8. 41ax9sj8ko

9. Rucaparib Camsylate [usan]

10. Bicyclo(2.2.1)heptane-1-methanesulfonic Acid, 7,7-dimethyl-2-oxo-, (1s,4r)-, Compd. With 8-fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-6h-pyrrolo(4,3,2-ef)(2)benzazepin-6-one (1:1)

11. Bicyclo[2.2.1]heptane-1-methanesulfonic Acid, 7,7-dimethyl-2-oxo-, (1s,4r)-, Compd. With 8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6h-pyrrolo[4,3,2-ef][2]benzazepin-6-one (1:1)

12. Rucaparib(camsylate)

13. Ag14699 Camsylate

14. Rucaparib Camphosulfonate

15. Rucaparib Camphorsulfonate

16. Chembl3833368

17. Rucaparib Camsylate [mi]

18. Schembl22817574

19. Amy9250

20. Chebi:134692

21. Dtxsid301027866

22. 8-fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6h-pyrrolo(4,3,2-ef)(2)benzazepin-6-one (7,7-dimethyl-2-oxobicyclo(2.2.1)heptan-1-yl)methanesulfonate (1:1)

23. Bcp18101

24. Ex-a3053

25. Rucaparib Camsylate [who-dd]

26. S5195

27. Cs-6939

28. Rucaparib Camsylate [orange Book]

29. Ac-30110

30. Hy-102003

31. A902311

32. Q27258428

33. ((1s,4r)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonic Acid - 8-fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one (1:1)

34. [4-(8-fluoro-6-oxo-3,4,5,6-tetrahydro-1h-azepino[5,4,3-cd]indol-2-yl)phenyl]-n-methylmethanaminium [(1s,4r)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl]methanesulfonate

35. 8-fluoro-5-(4-((methylamino)methyl)phenyl)-2,3,4,6-tetrahydro-1h-azepino[5,4,3-cd]indol-1-one ((1s,4r)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonate

2.3.2 Other Synonyms

1. 283173-50-2

2. Rubraca

3. Rucaparib

4. 8237f3u7eh

2.4 Create Date
2016-08-16
3 Chemical and Physical Properties
Molecular Weight 555.7 g/mol
Molecular Formula C29H34FN3O5S
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count7
Rotatable Bond Count5
Exact Mass555.22032053 g/mol
Monoisotopic Mass555.22032053 g/mol
Topological Polar Surface Area137 Ų
Heavy Atom Count39
Formal Charge0
Complexity869
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 1  
Drug NameRUBRACA
Active IngredientRUCAPARIB CAMSYLATE
CompanyCLOVIS ONCOLOGY INC (Application Number: N209115. Patents: 6495541, 7351701, 7531530, 8071579, 8143241, 8754072, 8859562, 9045487, 9861638)

4.2 Drug Indication

Treatment of fallopian tube cancer , Treatment of ovarian cancer , Treatment of primary peritoneal cancer , Treatment of prostate malignant neoplasms


Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY